Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Minnesota: Clinical Trials & FDA Approval Profile

University of Minnesota (Global / Institutional) sponsors 68 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 21 active protocols (17 recruiting now), 33 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)20.6%
Median Closed Enrollment vs National (145 pts)83 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Minnesota
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)68
Active Pipeline (Recruiting Now)21 (17)
Completed vs Stopped Early33 / 14 (20.6%)
Median Closed Actual Enrollment83 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of Minnesota
Hospital Research SiteLocationShared Protocols
University of MinnesotaMinneapolis, MN50
UT Southwestern Simmons Cancer CenterDallas, TX4
Washington University and Siteman Cancer CenterSaint Louis, MO3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University of Minnesota
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05605093Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)Phase IIITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the University of Minnesota Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI